Member Info for volmer

Sydney Sweeney is the way her name is spelt.

The influencer has to be Sidney Sweeney. At least I hope so.

Vascular, your posts are really good ones.

Just to remind ourselves of some of the facts behind Skin+Cell:

The products have been designed in collaboration with Marionnaud/Watsons to fill a gap in the top end of the market, so we have a high quality product that is market focussed.

It is a unique patented product. The only one that gets the treatment through the skin to the cells.

There are a lot of women, and men, in this world that want to protect their skin, to look more attractive, to prevent the signs of ageing and to protect against the damage caused by the sun. Just think about the number of women in the film industry, television, marketing and so on. I would guess that any woman would use products like this if they can afford it. But a heavy caveat - we have not tried it yet and we have not had customer feedback yet.

HIgh street retail is in a terrible state and dying. We know that. Rather than Watson selling the products on line why shouldn't Incanthera do it themselves. Influencers and direct marketing on line is the future and it's here now.

The skin moisturiser market in 2024 was $11bn.

If the distribution had taken place via Marionnaud/Watsons, Incanthera would have paid 50% of the gross margin to a partner. With the direct distribution channel, this is no longer the case. However, the direct marketing agency is working on a success based royalty model. I'm assuming they will get 10% of sales revenue. I'm assuming a 10% product cost and 10% for the agency, leaving an 80% gross margin.

Incanthera is at an early stage with this product and market. Delays will happen and mistakes will be made. We are all human. There are dozens of good AIM businesses out there that are selling at a fraction of fair value. As these businesses get de-risked the share prices increase. The same is true for Incanthera. Patience is not the most common attribute of private investors but many of these businesses will reward shareholders over time.

I will not say GLA as this usually means good luck me. Luck has little to do with investing IMO.

you know from my posts i’m mainly interested in facts and an assessment of the upside/downside, rather talking about short term emotions. management of any company is a key component of any assessment of that company. i have spent a lot of time researching everything necessary to make my best informed conclusion of the risk/reward here.

this work included looking at a management. i can see from the posts here and elsewhere that many others don’t seem to have done any deep research and have not fully understood the company and its management. this is not a criticism as everyone must do what they want.

i bought shares at 15p and i don’t **** off management because the price is below that currently. i also bought shares at 4p ish and i don’t praise management because the price the shares have more than doubled currently. everyone makes their own decision when to buy shares. if we are standing at a loss then we should look at ourselves and our decision making, and how we can improve it. if someone wants to express anger then we should direct it to ourselves for the decision we made and not always blame someone else imo.

i am not saying everything is perfect here. it is not, and never is. but think about marionnaud/watsons. management have just resolved successfully the unsubstantiated allegations about a patent. m have to assimilate this and decide how and when to launch the skin + cell products. this takes time. tm cannot speak for them, neither can he just press a button for full steam ahead. his team need to work with m to set out the way forward. then he can communicate with shareholders. remember the skin + cell products were developed in conjunction with m to meet the market niche they identified.

we can buy shares at the click of a button, it takes seconds. running a business is fraught with delays, the unexpected, successes, failures and it takes time and patience. much the same can be said about investing.

I expected the warrants to be extended as the funds could contribute to the funding of product production to supply the roll out of products planned by Marionnaud and to supply other potential customers. What I did not foresee was the clever move to base exercise price on 9.5p plus a 30% share of any increase in the Incanthera price. A sensible and clever move.

Lord, companies only need to provide important information in a situation such as this, generally that which is price sensitive. Once they start including other information such as that which some posters here have said they would like to have, then there is scope for it to be misconstrued.

The company has sales orders in place from Marionnaud and now the stocks can be bottled and delivered. If this was not the case then the information would have been price sensitive. So all is well.

When the share was at 4p it had a 100% downside and was a potential 100 bagger, if the price reaches 400p. The broker research note on 16 July 2024 had a valuation price of 200p. I think there could be more to come than was included in that note, e.g. other distribution deals. That was the big picture that we should not lose sight of, although the share price is now 12p.

Oldpro, if anything payment was due to Incanthera for making unsupported allegations that affected the company's trading and performance. But I guess, and it is a guess, that no payment has been received as any claim would likely have taken much too much time and could have involved legal action.

I suspect it is the company's best interest to proceed with delivering to its customer TS Watson/Marionnaud in accordance with the existing order.

As expected the allegations had no merit and a solid agreement is now in place that satisfactorily concludes the issue. This issue gave us the opportunity to acquire shares at 4p to 5p, in volume. Something most of us thought we would not see again.

TM has come out of this well and has done a good job in what must have been a difficult situation. It should give us all reassurance on the company's future. A major uncertainty has been removed.

Hosko, I think your post sums it up very well.

Next resistance level is 2.6p.

It is astonishing that they made the announcement before having secured the patent, if it is potentially worth as much as TM says. I should imagine the Chinese, hackers and others would try to steal the data before the patent has been secured. Stranger things have happened.

Hope this is not another Destiny Pharma.

Destiny had a multi million deal signed for their M3 product for Phase 3 and USA marketing. But delays followed. Then they failed to find a partner for their main product XF-73. And then they ended up de-listing from AIM.

The next resistance looks like being 2.6p.

Sorry, missed out “claim has been dealt with”

If the unsubstantiated patent challenge had any merit we would have heard by now.

Therefore, we should hear soon, either how the issue will be resolved or how the unsubstantiated claim has been

Andii, on podcast. Last Sunday Roast about 35 mins in.

The analyst Charles Archer has considered the aggressive USA growth, the warrant cash before commenting on future funding.

Some posters say no further placings required, fully funded. Others highlight sales, cash projections and uncertainty. These are some of the issues that make valuation very difficult. Funding is not black and white, its uncertain and its difficult finding out what needs to be de-risked and what price investors are prepared to pay now when the risks are greater.

Think we all agree sales prospects for Ondo are really good. Its a company we like to own. Have read forecasts for registered users and lor's recent post. How do you value a company like this? Its a stab in the dark.

As lor said some key issues are::

market cap £40m

full year sales to 31.3.25 est. at £5m

interim loss of £2.4m

interim cash burn used n operations £2.2m

In addition an analyst said he expects Ondo to need funding for global expansion, despite good sales funding model. He says global expansion is very expensive, you need a big backer and question is how much of company do you have to give up to make this happen.

OK, this is all unknown but that is the point. There are so many unknowns for a company expanding like this. The market is currently telling us that the price was too high and a lower price is expected.

Like lor I have been trying to like ONDO more but can’t get comfortable with the valuation.

Have read the recent posts with interest.

What struck me is that the benchmark price of 5p is generous to Langstead given the placing price of 3.75p. Langstead are professional financers and naturally are expert in these types of deals and negotiations. Just look at the past 6 financing deals with them. They produced the following results: gain to IMMU £0.6m, losses £0.9m, £1.0m, £1.7m, £0.7m and current loss of £0.2m. Thats a net loss of £3.9m. This is to be expected as its what Langstead are good at: finance.

So in all probability Langstead will make a profit on the current deal. What concerns me is that there appears to have been no competition in these fund raisings: they have all been with one company. Slam dunk for Langstead.

I don't get it! IMMU's business is pharma with all the risks that it entails. Why take finance risks as well; its not what they are good at and it has not paid off. But ending on a positive I think they were right to raise funds when not really needed: it gives them strength in negotiations.

Silence is golden. Please do not let us have an update until there is something concrete to report.

This is a tricky situation where a third party has made an substantiated claim. Patent lawyers, legal beagles and financial advisors will all be considering whether:

1. an agreement can be achieved with the third party, with or without damages

2. to sue them, or

3. to iron out any patent anomalies if the third party has provided any evidence, which appears not to be the case otherwise I suspect it would have been subject to a RNS.

You cannot give a running commentary on this but just report important developments.

Old pro, I want to think the same. It’s not the published trades that are moving the share price slowly upwards. But maybe a false dawn, I hope not.

Chris, perhaps bad news comes fast while good news takes longer. At least I hope so. INC’s patent lawyers must have been crawling all over this. If there was any validity in the claim we would have heard, surely! News must come soon.

The other party has made unfounded allegations. That we know. If so and they are proven to have no merit, then we should be looking at substantial damages.